12:00 AM
 | 
Feb 14, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Vyvanse lisdexamfetamine regulatory update

Health Canada approved an expanded label for Vyvanse lisdexamfetamine to treat ADHD to include the use in...

Read the full 63 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >